Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 348 of 348 entries
View as:

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

Phase: N/A Priority: Normal
NCT ID: NCT00288704 Org: User:
Start: 12/31/05 End: 08/31/08 Due: 08/31/09

Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06669234 Org: User:
Start: 03/06/25 End: 07/30/26 Due: 07/30/27

Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)

Phase: N/A Priority: Normal
NCT ID: NCT01910220 Org: User:
Start: 08/31/13 End: 10/31/14 Due: 10/31/15

Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

Phase: N/A Priority: Normal
NCT ID: NCT01997164 Org: User:
Start: 11/30/14 End: 10/31/15 Due: 10/31/16

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Phase: N/A Priority: Normal
NCT ID: NCT01730053 Org: User:
Start: 11/30/12 End: 05/31/14 Due: 05/31/15

Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06665828 Org: User:
Start: 03/04/25 End: 12/12/25 Due: 12/12/26

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

Phase: N/A Priority: Normal
NCT ID: NCT02713204 Org: User:
Start: 03/31/16 End: 10/03/17 Due: 10/03/18

Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01074372 Org: User:
Start: 03/31/10 End: 11/30/10 Due: 11/30/11

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

Phase: N/A Priority: Normal
NCT ID: NCT05259709 Org: User:
Start: 02/07/23 End: 07/28/25 Due: 07/28/26

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03889912 Org: User:
Start: 04/11/19 End: 10/22/27 Due: 10/22/28

Compassionate Use of Evinacumab

Phase: N/A Priority: Normal
NCT ID: NCT06500598 Org: User:
Start: - End: - Due: -

An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193

Phase: N/A Priority: Normal
NCT ID: NCT01933763 Org: User:
Start: 08/31/13 End: 01/31/15 Due: 01/31/16

Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

Phase: N/A Priority: Normal
NCT ID: NCT00856206 Org: User:
Start: 03/31/09 End: 01/31/11 Due: 01/31/12

Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT04287608 Org: User:
Start: 03/10/21 End: 03/29/23 Due: 03/29/24

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)

Phase: N/A Priority: Normal
NCT ID: NCT01720576 Org: User:
Start: 10/31/12 End: 06/30/13 Due: 06/30/14

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT01385657 Org: User:
Start: 07/31/11 End: 03/31/12 Due: 03/31/13

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT06541704 Org: User:
Start: 10/30/24 End: 05/21/32 Due: 05/21/33

Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase: N/A Priority: Normal
NCT ID: NCT03946748 Org: User:
Start: 05/16/19 End: 06/10/21 Due: 06/10/22

Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT02284425 Org: User:
Start: 10/31/14 End: 12/31/15 Due: 12/31/16

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03409614 Org: User:
Start: 03/06/18 End: 02/27/25 Due: 02/27/26

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Phase: N/A Priority: Normal
NCT ID: NCT02957682 Org: User:
Start: 11/02/16 End: 03/05/20 Due: 03/05/21

Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

Phase: N/A Priority: Normal
NCT ID: NCT04442269 Org: User:
Start: 09/15/20 End: 02/09/24 Due: 02/09/25

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

Phase: N/A Priority: Normal
NCT ID: NCT06836609 Org: User:
Start: 04/28/25 End: 03/01/27 Due: 03/01/28